30
Participants
Start Date
August 21, 2017
Primary Completion Date
March 6, 2019
Study Completion Date
April 23, 2019
LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection
LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
START Midwest, Grand Rapids
South Texas Accelerated Research Therapeutics, San Antonio
Lead Sponsor
Livzon Pharmaceutical Group Inc.
INDUSTRY